Impact of Non-Exudative Type 1 MNV on AMD Progression

Status Recruiting

Clinical Trial Summary

The overall goal of the proposed research project is to provide evidence that a specific subtype of neovascularization that may develop in eyes with age-related macular degeneration (AMD) prevents vision loss. This concept challenges the current view that the development of neovascularizations in AMD represents a harmful event in general. Notably, before the era of anti-vascular endothelial growths factor (VEGF) therapy, destruction and surgical removal of neovascular membranes have been tested as treatment options for neovascular AMD. This research project aims to substantiate the hypothesis that type 1 macular neovascularization (MNV) is intrinsically protective, in sense of a positive response to the degenerative processes in AMD. This concept has actually been proposed by pathologists decades ago but has not been systematically investigated in vivo. With the immense advances in retinal imaging, 'sub-clinical', non-exudative type 1 MNVs that are located beneath the retinal pigment epithelium (RPE) can now be detected non-invasively and characterized in vivo. There is currently a growing body of evidence that photoreceptor and RPE degeneration is indeed slowed down in eyes exhibiting type 1 MNV. However, the proof of a direct protective effect of non-exudative type 1 MNV on visual function in AMD is lacking. Here, the aim is to demonstrate relative preservation of function along with preserved structure in the immediate vicinity of type 1 MNV, while there is progressive loss of sensitivity and degeneration in the surrounding tissue.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06125977
Study type	Observational
Source	University of Utah
Contact	Christine Glasmann
Phone	801-585-6667
Email	christine.glasmann@hsc.utah.edu
Status	Recruiting
Phase
Start date	January 30, 2023
Completion date	August 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05984927` - NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT04101604` - Biomarkers of Common Eye Diseases
Completed	`NCT04005352` - Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)	Phase 3
Withdrawn	`NCT02873351` - A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration	Phase 2
Active, not recruiting	`NCT02802657` - Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration	Phase 4
Not yet recruiting	`NCT02864472` - Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose	Phase 4
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT01445548` - Sirolimus for Advanced Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT02035722` - Intravitreal Injections-related Anxiety	Phase 2/Phase 3
Completed	`NCT01175395` - 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)	Phase 1/Phase 2
Recruiting	`NCT01048476` - Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration	Phase 1/Phase 2
Active, not recruiting	`NCT01174407` - Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration	N/A
Terminated	`NCT00712491` - Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00345176` - Age-Related Eye Disease Study 2 (AREDS2)	Phase 3
Completed	`NCT02140151` - Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT02555306` - A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration	Phase 1/Phase 2
Recruiting	`NCT04796545` - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration	N/A
Completed	`NCT03166202` - Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
Completed	`NCT01397409` - Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)	Phase 2
Recruiting	`NCT06174181` - Preventive TREatment of Dry Eye in Patients Receiving Repeated Intravitreal Injections for Age-related Macular Degeneration	N/A